2021 CMSC Annual Meeting

Poster-Disease-modifying Therapy

Poster-Disease-modifying Therapy

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...

Read More

Poster-Disease-modifying Therapy

Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis

INTRODUCTION Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of relapsing forms of multiple...

Read More

Poster-Disease-modifying Therapy

Therapy Selection Considerations during the COVID-19 Pandemic Among Patients with Progressive Multiple Sclerosis: Analyses from Retrospective Patient Chart Audit

Background: In March 2020, the onset of the COVID-19 pandemic in the United States introduced new concerns related to the treatment of...

Read More

Poster-Disease-modifying Therapy

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohn’s Disease

Background: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P1 and S1P5, is approved in the US...

Read More

Poster-Disease-modifying Therapy

Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis

Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...

Read More

Poster-Disease-modifying Therapy

Clinical Outcomes in Patients with COVID-19 Infection during Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis

Background: The COVID-19 pandemic has become a significant concern for patients with multiple sclerosis (MS) and their healthcare...

Read More

Poster-Disease-modifying Therapy

Online Medical Education Increases Knowledge Among Neurologists of Safety Considerations for Disease Modifying Therapies in Multiple Sclerosis

Background: Disease modifying therapies (DMTs) have transformed the management of multiple sclerosis (MS). Patients can now live many years...

Read More

Poster-Disease-modifying Therapy

Classic-MS: Long-Term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Received Cladribine Tablets in Phase III Parent Trials

Background: CLASSIC-MS (NCT03961204) explores the long-term efficacy and durability of effect of cladribine tablets (CladT; cumulative dose...

Read More

Poster-Disease-modifying Therapy

Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis

Background: Limited data on baseline (BL) characteristics and disease severity exist for Black/African American (AA) patients with multiple...

Read More

Poster-Disease-modifying Therapy

Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the Asclepios I/II and Apolitos Studies

Background: Ofatumumab is a fully human anti-CD20 monoclonal antibody approved by the FDA for treatment of adults with relapsing multiple...

Read More